Jürgen provides scientific, regulatory and strategic support based on his extensive experience in the technical development of antibodies including design, affinity maturation, expression, protein purification and analytics. In addition, he has experience in the development of cell and gene therapy products. He was closely involved in cellular assay development, in vivo toxicity, pharmacokinetics, dose-response studies and in vivo models. Jürgen has a strong background in oncology, hematology, immunology and virology and supported all stages of drug development from preclinical to phase 1, 2 and 3 trials.
As biologist by training, Jürgen holds a PhD in biochemistry from the Eberhard Karls University in Tübingen. During his PhD, Jürgen was employed at Micromet AG (now Amgen) and investigated tumor immunotherapy by IL-2 and GM-CSF antibody cytokine fusion proteins.
After his PhD, he joined Roche Diagnostics GmbH as Laboratory Head and Project Leader in the preclinical development of antibodies, bispecific antibodies, antibody drug conjugates and antibody like scaffold fusion proteins. As Principal Scientist he was responsible for the development of biopharmaceuticals within multidisciplinary project teams from early target assessment until identification of a lead candidate for evaluation in phase 1 clinical studies. In 2018, Jürgen joined Morphosys AG as Lab Head Pharmacology and Immuno-Oncology Program Leader in the development of MOR210 (anti-C5aR Mab) enabling a phase 1 trial in collaboration with I-Mab Biopharma. At Morphosys, he was also supporting the preclinical and clinical development of tafasitamab (MOR208) in phase 2 & 3 trials in relapsed refractory DLBCL.
During his career as medical writer, he prepared several CTD sections for BLA filings, IBs, TPPs and briefing documents for regulatory agency meetings. Currently, he is finalizing the European Medical Writers Association (EMWA) Professional Development Programme (EPDP), which provides a high-quality training for medical writers.
Jürgen has a track record of scientific writing with 15 publications in peer reviewed journals, posters at conferences and more than 16 patents. Furthermore, he is speaker at numerous international conferences in the development of novel antibody therapeutics.